Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Oct 19;2(10):100431.
doi: 10.1016/j.xcrm.2021.100431. Epub 2021 Sep 30.

Unraveling the mechanisms of IVIG immunotherapy in MIS-C

Madhusudan Ganigara  1 , Chetan Sharma  2 , Jagadeesh Bayry  3
Affiliations
Comment

Unraveling the mechanisms of IVIG immunotherapy in MIS-C

Madhusudan Ganigara et al. Cell Rep Med. .

Abstract

In The Journal of Clinical Investigation, Zhu et al.1 report that intravenous immunoglobulin (IVIG) targets IL-1β+ neutrophils to exert anti-inflammatory effects in multisystem inflammatory syndrome in children (MIS-C), a post-infectious inflammatory condition associated with COVID-19.

PubMed Disclaimer

Conflict of interest statement

J.B. (at Institut National de la Santé et de la Recherche Médicale, Centre de Recherche des Cordeliers, Paris, France) has received research grants from CSL Behring, France, for investigation on the mechanisms of action of IVIG.

Figures

Figure 1
Figure 1
IVIG targets IL-1β+ neutrophils to exert anti-inflammatory effects in MIS-C and Kawasaki disease (KD) MIS-C and KD patients display enhanced frequency of IL-1β+ neutrophils with an upregulated activation and adhesion molecules. Zhu et al. report that IVIG therapy reduces IL-1β+ neutrophils and their activation markers. Mechanistically, IVIG induced neutrophil death by phosphatidylinositol 3-kinase and NADPH oxidase pathways. The figure was created with the support of https://biorender.com.
See this image and copyright information in PMC

Comment on

  • Immune response to intravenous immunoglobulin in patients with Kawasaki disease and MIS-C.
    Zhu YP, Shamie I, Lee JC, Nowell CJ, Peng W, Angulo S, Le LN, Liu Y, Miao H, Xiong H, Pena CJ, Moreno E, Griffis E, Labou SG, Franco A, Broderick L, Hoffman HM, Shimizu C, Lewis NE, Kanegaye JT, Tremoulet AH, Burns JC, Croker BA; Pediatric Emergency Medicine Kawasaki Disease Research Group Consortium. Zhu YP, et al. J Clin Invest. 2021 Oct 15;131(20):e147076. doi: 10.1172/JCI147076. J Clin Invest. 2021. PMID: 34464357 Free PMC article.

References

    1. Zhu Y.P., Shamie I., Casey Lee J., Nowell C.J., Peng W., Angulo S., Le L.N., Liu Y., Miao H., Xiong H. Immune response to intravenous immunoglobulin in patients with Kawasaki disease and MIS-C. J. Clin. Invest. 2021:147076. doi: 10.1172/JCI147076. - DOI - PMC - PubMed
    1. Lee M.S., Liu Y.C., Tsai C.C., Hsu J.H., Wu J.R. Similarities and differences between COVID-19-related multisystem inflammatory syndrome in children and Kawasaki disease. Front Pediatr. 2021;9:640118. doi: 10.3389/fped.2021.640118. - DOI - PMC - PubMed
    1. Henderson L.A., Canna S.W., Friedman K.G., Gorelik M., Lapidus S.K., Bassiri H., Behrens E.M., Ferris A., Kernan K.F., Schulert G.S. American College of Rheumatology clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: Version 2. Arthritis Rheumatol. 2021;73:e13–e29. doi: 10.1002/art.41616. - DOI - PMC - PubMed
    1. Syrimi E., Fennell E., Richter A., Vrljicak P., Stark R., Ott S., Murray P.G., Al-Abadi E., Chikermane A., Dawson P. The innate and adaptive immune landscape of SARS-CoV-2-associated multisystem inflammatory syndrome in children (MIS-C) from acute disease to recovery. medRxiv. 2021 doi: 10.1101/2020.08.06.20164848. Published online March 29, 2011. - DOI - PMC - PubMed
    1. Bartsch Y.C., Wang C., Zohar T., Fischinger S., Atyeo C., Burke J.S., Kang J., Edlow A.G., Fasano A., Baden L.R. Humoral signatures of protective and pathological SARS-CoV-2 infection in children. Nat. Med. 2021;27:454–462. doi: 10.1038/s41591-021-01263-3. - DOI - PMC - PubMed

Publication types

Substances

Supplementary concepts

LinkOut - more resources